QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 0.4938
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 06-14-2024 04-30-2024 10-Q
2 03-18-2024 01-31-2024 10-Q
3 12-14-2023 10-31-2023 10-Q
4 10-25-2023 07-31-2023 10-K
5 06-14-2023 04-30-2023 10-Q
6 03-16-2023 01-31-2023 10-Q
7 12-14-2022 10-31-2022 10-Q
8 10-28-2022 07-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-briacell-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

 why-is-breast-cancer-focused-briacell-therapeutics-stock-trading-over-100-on-wednesday

BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast c...

Core News & Articles

BCTX: 143% | BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Br...

 briacell-therapeutics-says-received-positive-feedback-from-its-pre-investigational-new-drug-application-meeting-with-fda-for-bria-pros-in-prostate-cancer

As a result of the Pre-IND meeting, FDA waived the animal toxicology and animal pharmacokinetic (PK) studies requirement for op...

 briacell-reports-extended-progression-free-survival-to-91-months-in-adc-resistant-metastatic-breast-cancer-patient-top-responder-continues-bria-imt-treatment-in-phase-2-study

Previously Reported Significant Reduction Of "Eye-Bulging" Tumor; Patient Had Failed 8 Prior Regimens

 hc-wainwright--co-reiterates-buy-on-briacell-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

 briacell-presents-clinical-efficacy-data-of-randomized-phase-2-study-evaluating-bria-imt-in-patients-with-advanced-metastatic-breast-cancer-at-asco-2024

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

 briacell-doubles-progression-free-survival-and-reports-clinical-data-of-bria-imt-asco-2024

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS m...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION